Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved tavapadon (brand name: Juvmo), AbbVie's new once-daily pill for Parkinson's disease in adults. The drug works by mimicking dopamine — the brain chemical that diminishes in Parkinson's patients — and was shown to improve symptoms in late-stage trials. AbbVie acquired the drug through its $8.7 billion purchase of Cerevel Therapeutics in 2023.
The FDA has officially approved Juvmo (tavapadon), AbbVie's once-daily oral treatment for Parkinson's disease in adults. The drug works by mimicking dopamine, the brain chemical that naturally declines in people with Parkinson's, leading to hallmark symptoms like tremors, stiffness, and balance problems. Approval was based on data from AbbVie's late-stage clinical trial program, which demonstrated meaningful symptom improvement in patients.
AbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023. Common side effects observed in trials included nausea, dizziness, and headache. Pricing and launch timing remain in flux, with Citi analysts previously projecting a gradual rollout starting in Q3 2026, pending Medicare coverage negotiations.
By the Numbers:
Why it matters: Juvmo offers patients a convenient once-daily pill option for managing Parkinson's — a disease with limited treatment choices. For clinicians, it represents a new dopamine-mimicking treatment option, though real-world uptake will depend heavily on how Medicare coverage negotiations unfold.
